Is the PASCAL Device Effective against MitraClip?

Mitral regurgitation (MR) is the most common valvulopathy and full medical treatment at maximal tolerated doses has been shown quite effective to treat it. However, its limited in a group of patients that require valve intervention. 

¿Es efectivo el dispositivo PASCAL comparado con MitraClip?

At present, the ideal treatment is surgical valve replacement, which is in many cases is not viable because of its high surgical risk. It is in this scenario where Edge-to-edge with MitraClip has been shown beneficial. 

Currently, there is another device available, the PASCAL, but its safety and efficacy has not been yet analyzed against the MitraClip. 

The CLASP IID is a randomized, multicenter, multinational, prospective study assessing the safety and efficacy of the PASCAL against MitraClip in patients with degenerative mitral regurgitation with prohibitive risk of surgery. 

Safety end point was the composite of MAE at 30 days (cardiovascular death, MI, stroke, need for dialysis, major bleeding and surgical or percutaneous non-elective reintervention of the mitral valve) and effective end point was the presence of MI ≤2 + at 6 months.

It included 180 patients, 117 receiving PASCAL and 63 MitraClip.

Read also: Combined Calcified Lesion Preparation Strategy.

Mean age was 81, 66% were men, 85% had hypertension, 18% diabetes, and 58% atrial fibrillation.

75% of mitral regurgitation was grade 4+, effective orifice area was 0.50 cm2, ejection fraction 58%, diastolic volume 145, pulmonary artery systolic pressure 43 mmHg, TAPSE 20, atrial volume 120 ml and severe tricuspid failure 3%.

Primary safety end point at 30 days was similar (3.4% for PASCAL vs. 4.8% for MitraClip), showing non-inferiority between devices. There was no difference in mortality, stroke, MI, need for dialysis, major bleeding and non-elective mitral valve intervention. 

Read also: Is Clopidogrel Monotherapy Safe After a Month of Dual Antiplatelet Therapy in Diabetic Patients?

Efficacy end point at 6 months also resulted similar, meeting non-inferiority criteria (96.5% for PASCAL vs. 96.8% for MitraClip).

Conclusion

the CLASP IID showed PASCAL system met non-inferiority primary end points expanding percutaneous treatment as a valid option for patients with symptomatic degenerative mitral valve regurgitation at prohibitive surgical risk.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board SOLACI.org.

Original Title: Randomized Comparison of Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation in Prohibitive Surgical Risk Patients.

Reference: D. Scott Lim, M. J Am Coll Cardiol Intv 2022;15:2523–2536.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...